Novartis and Novo helped provide $40m for the EPFL spinout that supported its acquisition of joint venture Kanyos Bio.

The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.

Existing investor Samsung Next returned for a $60m series C round as Healthy.io secured regulatory clearance for its app-based kidney disease test.

Praktikertjänst-backed Aprea Therapeutics has filed for a $68.3m initial public offering that will fund the clinical progress of its cancer drug candidates.

The immuno-oncology drug developer, which counts numerous pharmaceutical firms among its investors, has filed for a $100m offering in the US.

Karolinska Institute spinout Aprea Therapeutics has filed to raise approximately $68.3m in an IPO that will see it list on the Nasdaq Global Select Market.

Institut Mérieux has returned for a $26.5m round for surgical technology developer Keranova, having previously supported a $4.6m round three and a half years ago.

Institut Mérieux has returned for a $26.5m round for surgical technology developer Keranova, having previously supported a $4.6m round three and a half years ago.

Fosun Pharma is in line to exit Shanghai Henlius Biotech, which has set a price range for an offering that could raise up to $477m.

Spirogen spinoff ADC will put the proceeds into advancing its cancer-fighting antibody drug conjugates, having raised more than $530m from backers including AstraZeneca.